Crisil Lifts NGL Fine-Chem Outlook to Stable

Crisil Ratings has moved NGL Fine-Chem Limited's long-term credit rating outlook from 'Negative' to 'Stable'. The agency also reaffirmed the company's existing ratings: 'Crisil BBB+' for long-term bank loan facilities and 'Crisil A2' for short-term facilities. This marks a significant reversal from the 'Negative' outlook assigned in June 2025.

Background: Reversing the Negative Trend

Last year, Crisil had revised NGL Fine-Chem's outlook to 'Negative' primarily due to a sharp moderation in operating margins, which fell to 10.2% in fiscal 2025 from around 17% in fiscal 2024. This margin decline was attributed to increased competition affecting prices and higher operating costs, including salaries and job work. Consequently, the company's accruals reduced to Rs 32 crore in FY25.

However, the company demonstrated resilience in fiscal 2024, achieving 21.8% year-over-year revenue growth and an improved operating profit margin of 15.9%, driven by demand recovery and better realisations. Recent quarterly results for Q3 FY26 further highlight a strong turnaround. Revenue jumped 48.5% year-over-year to ₹132.12 crore, with net profit surging 1125.78% to ₹15.69 crore.

Implications for NGL Fine-Chem

This 'Stable' outlook suggests Crisil believes NGL Fine-Chem's financial performance and credit profile have improved sufficiently to address prior concerns. The upgrade can lead to better borrowing terms, lower interest costs, and enhanced investor confidence, potentially facilitating easier and cheaper access to debt financing for its expansion plans.

Expansion and Financials

NGL Fine-Chem is currently undertaking a significant greenfield expansion at Tarapur, with an estimated outlay of Rs 160 crore. This expansion is being funded through a mix of debt and internal accruals. For the nine months ended March 2024 (9M FY2024), revenue stood at approximately Rs 239 crore (19.5% YoY growth) with operating margins at 15.8%.

Remaining Risks

Despite the positive rating revision, potential vulnerabilities remain. The company's profitability is susceptible to raw material price volatility. There is also a high product concentration risk, with a significant focus on animal health APIs. Large working capital requirements continue to be a factor, and the impact of the ongoing capital expenditure on financial metrics will be a key monitorable.

Industry Comparison

NGL Fine-Chem operates in the competitive API and intermediates sector alongside major players like Divi's Laboratories, Laurus Labs, Aarti Drugs, and Torrent Pharmaceuticals. While its scale is moderate compared to giants like Divi's Labs, its focus on veterinary APIs offers a distinct niche. The company's recent performance indicates it is regaining momentum, crucial in a sector driven by innovation and stringent quality standards.

Future Focus Areas

Investors and analysts will monitor several key areas: the execution of the Rs 160 crore greenfield expansion at Tarapur, the sustainability of improved operating margins amidst competition and cost pressures, the successful introduction of new products expected to support revenue, efficient working capital management, and continued revenue growth and profitability improvements in upcoming quarterly results.